Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
Want to see ALLR full AI Analyst Report?
Top Page
Allarity Therapeutics
(NASDAQ:ALLR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(31.58% Upside)
Action:ReiteratedDate:05/09/26
Overall score reflects weak fundamental financial performance (limited revenue, ongoing losses, historical cash burn) partially offset by strong technical momentum (price above major moving averages with positive MACD). Corporate events are mixed, with restrictive financing terms tempering otherwise positive pipeline/visibility updates, and valuation signals are constrained by negative earnings and no dividend data.
Positive Factors
Intellectual Property / Competitive Moat
A granted patent for the DRP companion diagnostic creates a durable competitive barrier around stenoparib patient selection. Exclusive diagnostic rights through 2039 strengthen commercialization leverage, licensing prospects, and partner incentives, supporting long-term revenue optionality once paired with an approved therapy.
Negative Factors
Historic Cash Burn
Multi-year negative operating and free cash flow indicate persistent cash burn typical of clinical-stage biotech, requiring recurring external capital. Long-term funding dependence raises dilution risk, can disrupt development timelines, and constrains strategic choices until commercial cash generation emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Intellectual Property / Competitive Moat
A granted patent for the DRP companion diagnostic creates a durable competitive barrier around stenoparib patient selection. Exclusive diagnostic rights through 2039 strengthen commercialization leverage, licensing prospects, and partner incentives, supporting long-term revenue optionality once paired with an approved therapy.
Read all positive factors
Allarity Therapeutics (ALLR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.52M
Dividend YieldN/A
Average Volume (3M)146.33K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue GrowthN/A
EPS Growth99.89%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding15,818,980
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue35.10
Enterprise Value/Gross Profit35.10
Enterprise Value/Ebitda-1.02
Forecast
1Y Price Target
$9.75Price Target Upside755.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Allarity Therapeutics Business Overview & Revenue Model
Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenopa...
How the Company Makes Money
null...
Allarity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 320.00K | 0.00 | -37.00K | -120.00K | -106.00K |
| EBITDA | -11.05M | -24.23M | -11.28M | -17.30M | -25.77M |
| Net Income | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
Balance Sheet | |||||
| Total Assets | 18.26M | 22.65M | 11.86M | 14.54M | 49.63M |
| Cash, Cash Equivalents and Short-Term Investments | 14.69M | 19.53M | 166.00K | 2.03M | 19.91M |
| Total Debt | 1.40M | 1.35M | 1.30M | 3.73M | 1.09M |
| Total Liabilities | 8.43M | 10.84M | 14.61M | 12.65M | 30.85M |
| Stockholders Equity | 9.83M | 11.81M | -2.75M | 1.89M | 18.78M |
Cash Flow | |||||
| Free Cash Flow | -14.83M | -17.65M | -12.74M | -16.84M | -15.05M |
| Operating Cash Flow | -14.82M | -17.35M | -12.74M | -16.82M | -15.05M |
| Investing Cash Flow | -8.00K | -298.00K | 0.00 | 791.00K | 1.00M |
| Financing Cash Flow | 10.65M | 36.79M | 10.99M | -1.31M | 33.82M |
Allarity Therapeutics Technical Analysis
Positive
1.14
Price Trends
1.08
Positive
1.10
Positive
1.20
Positive
Market Momentum
0.03
Negative
57.27
Neutral
69.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Positive. The current price of 1.14 is below the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.08, and below the 200-day MA of 1.20, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 57.27 is Neutral, neither overbought nor oversold. The STOCH value of 69.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLR.
Allarity Therapeutics Risk Analysis
Allarity Therapeutics disclosed 87 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allarity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $24.52M | -1.15 | -112.05% | ― | ― | 99.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $28.69M | -1.37 | -84.39% | ― | -83.00% | 20.34% | |
44 Neutral | $19.67M | -0.53 | -119.92% | ― | -49.87% | 67.92% | |
43 Neutral | $22.43M | 1.68 | 354.21% | ― | -13.43% | 83.03% |
* Healthcare Sector Average
ALLR
Allarity Therapeutics
1.55
0.53
51.96%
LSTA
Lisata Therapeutics
3.15
0.93
41.64%
CRIS
Curis
0.56
-1.40
-71.38%
LGVN
Longeveron
0.85
-0.63
-42.52%
Allarity Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Allarity Highlights Stenoparib Progress in New Investor Presentation
Positive
May 8, 2026
Allarity Therapeutics said it will begin using a new corporate presentation with investors, analysts and other audiences starting May 11, 2026, outlining its DRP companion diagnostics platform and the clinical progress of its lead asset stenoparib...
Business Operations and StrategyPrivate Placements and Financing
Allarity Therapeutics Secures $20 Million Structured Note Financing
Negative
Mar 6, 2026
On March 2, 2026, Allarity Therapeutics entered into a note purchase agreement with Streeterville Capital under which it issued an unsecured A-1 promissory note with an original principal amount of $10.93 million and a secured B note of $10 millio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.